ONCOLYTICS BIOTECH INC

8-K · oncy-20260601.htm iXBRL

0001129928 2026-01-08 2026-01-08

 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 ___________________________________
 FORM 8-K
 ___________________________________
 CURRENT REPORT
 Pursuant to Section 13 or 15(d)
 of the Securities Exchange Act of 1934

 Date of Report (Date of earliest event reported): June 1, 2026
 ___________________________________
 Oncolytics Biotech Inc.
 (Exact name of registrant as specified in its charter)
 ___________________________________

 Nevada
 (State or other jurisdiction of
 incorporation)
 001-38512
 (Commission File Number)
 98-0541667
 (IRS Employer Identification No.)

 4350 Executive Drive , Suite 325
 San Diego , CA 92121
 92121

 (Address of principal executive offices)
 (Zip Code)

 ( 403 ) 670-7377

 (Registrant's telephone number, including area code)

 N/A

 (Former name or former address, if changed since last report)

 ___________________________________
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 ☐
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 ☐
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 ☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 ☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:

 Title of each class
 Trading Symbol(s)
 Name of each exchange on which registered

 Common stock, par value $0.001 per share
 ONCY
 The Nasdaq Stock Market LLC

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).
 Emerging growth company     ☐
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 Item 8.01. Other Events.
 On June 1, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing initial preclinical data for pelareorep in combination with RAS inhibitor modalities and plans for additional studies evaluating pelareorep in combination with multiple RAS-targeted agents. The information set forth in this Item 8.01 and in Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

 Item 9.01. Financial Statements and Exhibits.
 (d) Exhibits.

 Exhibit No.
 Description

 99.1
 Press Release issued by Oncolytics Biotech Inc., dated as of J u n e 1 , 2026 .

 104
 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 SIGNATURE

 Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Date: June 1, 2026

 ONCOLYTICS BIOTECH INC.

 By:
 /s/ Kirk Look

 Name:
 Kirk Look

 Title:
 Chief Financial Officer